Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42165279 in MDD with Anxious Distress
NCT02498392Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of JNJ-42165279 in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Oct 2015; status: completed.
02
Drugs
JNJ-42165279
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02498392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498392.